Liang Zhou

Liang Zhou is a Scientist III at Asklepios BioPharmaceutical, Inc. since January 2022, specializing in the molecular mechanisms that affect cancer cells' responses to targeted therapies, with a focus on novel treatment strategies for hematologic malignancies. Prior experience includes serving as an Instructor at Virginia Commonwealth University from July 2011 to January 2022, where responsibilities involved research on molecular targets in multiple myeloma, leukemia, and lymphoma, as well as studying the role of FoxO1 in prostate cancer as a Postdoctoral Scholar. Liang Zhou holds a PhD in Cell/Cellular and Molecular Biology from Northeast Normal University and an MD in Clinical Medicine from Jilin University.